Peter L Greenberg MD

Hematologic Oncology

Professor Emeritus, Medicine - Hematology, Stanford University Medical Center

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1970 - 1971
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1967 - 1970
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1963 - 1965
George Washington University School of Medicine and Health SciencesClass of 1963

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

PubMed

Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.
Alfonso Molina, Vishesh Khanna, Alexandria Jensen, Henning Stehr, Brent Tan
Leukemia Research. 2025-09-01
2 citations
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
Blood. 2025-03-27
5 citations
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Peter L Greenberg, Richard M Stone, Yasmin Abaza, Aref Al-Kali, Sarah Anand
Journal of the National Comprehensive Cancer Network. 2025-03-01

Journal Articles

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola..., Blood, 9/2013

Abstracts/Posters

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
Peter L Greenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents
Peter L Greenberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Highlights of ASH® San Diego, CA
American Society of Hematology (ASH), San Diego, California - 1/18/2013

$Stanford Study Finds That Notable’s Drug Sensitivity Screening Platform Can Identify Potentially Useful Drugs for MDS Patients Refractory to Standard Therapies$
Stanford Study Finds That Notable’s Drug Sensitivity Screening Platform Can Identify Potentially Useful Drugs for MDS Patients Refractory to Standard TherapiesJune 23rd, 2020
In Personalized Medicine Feasibility Study, Stanford Medical Center, with Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer PatientsApril 15th, 2019

Clinical Trial: Subjects With (MDS) Receiving Hypomethylatin AgentsNational Center For Research Resources2008
Monoclonal Antibody Therapy For Myelodysplastic SyndromeNational Center For Research Resources2005
Safety And Efficacy Trial Of Bevacizuman: Anti-Vegf MABNational Center For Research Resources2004
A Phase I Study Of Zarnestra And Gleevec In PatientsNational Center For Research Resources2004
Mitoxantrone, Etoposide, Cytarabine, PSC 833 In AMLNational Center For Research Resources2000–2001
Phase I Clinical Trial Of Vincristine, Adriamycin And Others In Relapse MyelomaNational Center For Research Resources1997–1999
Cellular And Humoral Modulation Of HemopoiesisNational Cancer Institute1988–1990
Cellular Modulation Of HemopoiesisNational Cancer Institute1985–1989